Streetbeat News

Analyst Ratings

BERY

Citigroup analyst Anthony Pettinari maintains a Buy rating on Berry Global Gr (NYSE:BERY) and raises the price target from $72 to $79.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:36 pm

BALL

Citigroup analyst Anthony Pettinari has maintained a Neutral rating on Ball (NYSE:BALL) and lowered the price target from $61 to $60.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:35 pm

AVY

Citigroup analyst Anthony Pettinari has reiterated a 'Buy' rating on Avery Dennison (NYSE:AVY) and maintained a price target of $200.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:33 pm

NBIX

Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a $130 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:33 pm

AMD

Morgan Stanley reports that DigiTimes has stated AMD must delay the roll out of its MI300X in order to enhance its performance.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:33 pm

APG

Citigroup analyst Andrew Kaplowitz maintains a 'Buy' rating on APi Gr (NYSE:APG) and raises the price target from $28 to $32.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:33 pm

MPLX

Morgan Stanley analyst Robert Kad has reiterated an Equal-Weight rating on MPLX (NYSE:MPLX) and maintained a $42 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:32 pm

AMBP

Citigroup analyst Anthony Pettinari has reiterated a 'Buy' rating on Ardagh Metal Packaging (NYSE:AMBP) and maintained a price target of $5.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:31 pm

MRNA

Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Moderna (NASDAQ:MRNA) and lowered the price target from $153 to $128.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:31 pm

IOVA

Iovance Biotherapeutics Inc's shares are trading lower after the company announced the pricing of a public offering of 20 million shares at $7.50 per share, expected to raise approximately $150 million. The proceeds will be used to fund preparations for the commercial launch of lifileucel, support the development of the company's pipeline candidates, and support Proleukin integration activities. Despite the drop, Truist Securities and Chardan Capital analysts reiterated a Buy rating for Iovance, with price targets of $17 and $29 respectively.

Portfolio Pulse from Adam Eckert

July 11, 2023 | 1:30 pm